Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study

Published:2020-05-04 Issue:14 Volume:26 Page:3517-3524
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Posadas Edwin M.,Chi Kim N.,de Wit Ronald,de Jonge Maja J.A.,Attard Gerhardt,Friedlander Terence W.,Yu Margaret K.,Hellemans Peter,Chien Caly,Abrams Charlene,Jiao Juhui J.,Saad Fred

Funder

J&J | Janssen Research and Development

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer;Oncogene;2024-03-13

2. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial);Journal of Clinical Oncology;2023-06-20

3. A chemoenzymatic process for preparation of highly purified dehydroepiandrosterone in high space-time yield;Bioorganic Chemistry;2023-04

4. Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer;British Journal of Cancer;2023-01-26

5. A narrative review of the role of glucocorticoid receptors in prostate cancer: developments in last 5 years;Translational Andrology and Urology;2022-08